Biological Assessment and Tests of Activity of Two Novel Proteolysis Targeting Chimeras (PROTACs)

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Notes: Heidelberg, Universität Heidelberg, Dissertation, 2022

Keyword: Proteolysis
Examinations
Evaluation
PROTAC
Targeted protein degradation
Proteasomal degradation

Event: Veröffentlichung

(where): Heidelberg

(who): Universitätsbibliothek Heidelberg

(when): 2022

Creator: Gama Brambila, Rodrigo

Contributor: Wölfl, Stefan

DOI: 10.11588/heidok.00031644

URN: urn:nbn:de:bsz:16-heidok-316445

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Gama Brambila, Rodrigo
Wölfl, Stefan
Universitätsbibliothek Heidelberg

Time of origin

2022

Other Objects (12)

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity

Selektive HDAC6-Inhibitoren und „Proteolysis Targeting Chimeras“ (PROTACs): Synthese und biologische Testung

Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)

Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10

HaloTag‐targeted sirtuin‐rearranging ligand (SirReal) for the development of proteolysis‐targeting chimeras (PROTACs) against the lysine deacetylase sirtuin 2 (Sirt2)

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity

Selektive HDAC6-Inhibitoren und „Proteolysis Targeting Chimeras“ (PROTACs): Synthese und biologische Testung

Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)

Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10

HaloTag‐targeted sirtuin‐rearranging ligand (SirReal) for the development of proteolysis‐targeting chimeras (PROTACs) against the lysine deacetylase sirtuin 2 (Sirt2)

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity

Selektive HDAC6-Inhibitoren und „Proteolysis Targeting Chimeras“ (PROTACs): Synthese und biologische Testung

Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)

Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10

HaloTag‐targeted sirtuin‐rearranging ligand (SirReal) for the development of proteolysis‐targeting chimeras (PROTACs) against the lysine deacetylase sirtuin 2 (Sirt2)

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Biological Assessment and Tests of Activity of Two Novel Proteolysis Targeting Chimeras (PROTACs)

Object Details

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity

Selektive HDAC6-Inhibitoren und „Proteolysis Targeting Chimeras“ (PROTACs): Synthese und biologische Testung

Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)

Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10

HaloTag‐targeted sirtuin‐rearranging ligand (SirReal) for the development of proteolysis‐targeting chimeras (PROTACs) against the lysine deacetylase sirtuin 2 (Sirt2)

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity

Selektive HDAC6-Inhibitoren und „Proteolysis Targeting Chimeras“ (PROTACs): Synthese und biologische Testung

Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)

Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10

HaloTag‐targeted sirtuin‐rearranging ligand (SirReal) for the development of proteolysis‐targeting chimeras (PROTACs) against the lysine deacetylase sirtuin 2 (Sirt2)

Proteolysis targeting chimeras (PROTACs) for epigenetics research

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis targeting chimeras (PROTACs) in cancer therapy

Proteolysis Targeting Chimeras (PROTACs) in Breast Cancer Therapy

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity

Selektive HDAC6-Inhibitoren und „Proteolysis Targeting Chimeras“ (PROTACs): Synthese und biologische Testung

Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)

Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10

HaloTag‐targeted sirtuin‐rearranging ligand (SirReal) for the development of proteolysis‐targeting chimeras (PROTACs) against the lysine deacetylase sirtuin 2 (Sirt2)

Related objects

Reset password